Novartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM

 

  • COMBI-AD is first trial to demonstrate 5-year relapse-free survival with targeted therapy as adjuvant treatment in high-risk patients with stage III BRAF-mutated melanoma1
     
  • Adjuvant treatment with standard-of-care targeted therapy Tafinlar + Mekinist reduced the risk of relapse or death by 49% compared to placebo1
     
  • Updated data show Tafinlar + Mekinist improved distant metastasis-free survival, a secondary endpoint1

             
Basel, September 16 …

/by

Committed to increasing access

Patient and healthcare worker in Vietnam

Novartis reinforces its commitment to environmental, social and governance (ESG) principles and the …

/by

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond

  • First healthcare industry sustainability-linked bond (SLB) further embeds Environmental Social Governance (ESG) targets into the core of Novartis business operations

  • SLB linked to 2025 Patient Access Targets to increase patients reached in low- and middle-income countries (LMICs) with strategic innovative therapies by 200% and the Novartis Flagship Programs by 50%

Basel, September 16, 2020 — Novartis today announced the pricing of a EUR 1.85 billion sustainability-linked bond (SLB), reinforcing its commitment to ESG …

/by